Inogen, Inc (INGN) News
Filter INGN News Items
INGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INGN News Highlights
- For INGN, its 30 day story count is now at 6.
- Over the past 29 days, the trend for INGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about INGN are AVNS and BEAT.
Latest INGN News From Around the Web
Below are the latest news stories about Inogen Inc that investors may wish to consider to help them evaluate INGN as an investment opportunity.
Inogen Announces Fourth Quarter and Full Year 2021 Financial ResultsGOLETA, Calif., February 24, 2022--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and twelve-month periods ended December 31, 2021. |
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue EstimatesAvanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Inogen (INGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Inogen (INGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Inogen (NASDAQ:INGN) shareholders have endured a 78% loss from investing in the stock three years agoIt's not possible to invest over long periods without making some bad investments. But really big losses can really... |
Hunter Associates Investment Management Llc Buys BTC iShares Floating Rate Bond ETF, II-VI Inc, ...Investment company Hunter Associates Investment Management Llc (Current Portfolio) buys BTC iShares Floating Rate Bond ETF, II-VI Inc, Thermo Fisher Scientific Inc, Broadcom Inc, Nasdaq Inc, sells Medtronic PLC, Netflix Inc, Gilead Sciences Inc, Alphabet Inc, Intel Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hunter Associates Investment Management Llc. |
Inogen to Announce Fourth Quarter 2021 Financial Results on February 24, 2022GOLETA, Calif., January 26, 2022--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter 2021 financial results after market close on Thursday, February 24, 2022. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. |
Riverbridge Partners Llc Buys Amedisys Inc, Privia Health Group Inc, Progyny Inc, Sells Gentex ...Minneapolis, MN, based Investment company Riverbridge Partners Llc (Current Portfolio) buys Amedisys Inc, Privia Health Group Inc, Progyny Inc, Five9 Inc, PayPal Holdings Inc, sells Gentex Corp, Healthcare Services Group Inc, Maximus Inc, Rogers Corp, National Instruments Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Riverbridge Partners Llc. |
Inogen's (INGN) Preliminary Q4 Revenues Solid Amid ChallengesInogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints. |
Inogen (INGN) Receives a Hold from Leerink PartnersLeerink Partners analyst Danielle Antalffy maintained a Hold rating on Inogen (INGN – Research Report) yesterday. The company's shares closed last Tuesday at $30.73, close to its 52-week low of $29.28. According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 10.3% and a 54.2% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts. Inogen has an analyst consensus of Hold, with a price target consensus of $44.00. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $82.35 and a one-year low of $29.28. |
Needham Sticks to Their Buy Rating for Inogen (INGN)E ratio of 66.21. |